Delivery Order SPE2DB20D1100-SPE2DB25FC6H9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,530.62 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of September 17, 2025. This competitive award uses firm fixed pricing with no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,213.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of July 29, 2025. The contract, issued on July 28, 2025, employs firm fixed-price pricing and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $2,457.00 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitive, firm fixed-price delivery order was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $5,864.45 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 4, 2025, with completion targeted for September 5, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a delivery order valued at $2,334.15 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. The award, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfilled this requirement as a competitive award under its existing contract vehicle with the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This non-set-aside, competitively awarded contract was issued on September 16, 2025, with an ultimate completion date of September 17, 2025, and reflects a firm fixed-price delivery order structure. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a $1,037.40 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors under a firm fixed price contract with an ultimate completion date of July 15, 2025. The award, issued on July 14, 2025, represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention and treatment,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Emgality 120 mg/ml pen injectors, valued at $3,458.00. This firm fixed-price contract, which is non-set-aside and competitively awarded, is scheduled for completion by August 7, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,309.49 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on May 20, 2025, with an ultimate completion date of May 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication, reflecting the company's role as a...
- The Defense Logistics Agency (DLA) awarded a $3,457 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitive, firm fixed-price contract was issued without set-aside designation and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The product—Emgality (erenumab)—is a monoclonal antibody used for migraine prevention, reflecting the...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FC6H9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitively awarded, firm fixed-price delivery order was issued on June 2, 2025, with an ultimate completion date of June 3, 2025. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for migraine prevention, representing a specialized pharmaceutical product within the federal medical supply chain. As a major pharmaceutical distributor serving military and veteran healthcare systems, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications through its DLA contracts. This delivery order exemplifies the company's role in supporting Defense Health Agency pharmaceutical procurement needs through the DLA's comprehensive global pharmaceutical support program, which enables flexible ordering of a wide range of medical commodities to support military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 6/2/25 |